Pfizer’s Inclacumab Study: A Potential Game-Changer for Sickle Cell Disease

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.

Pfizer Inc. is conducting a study titled ‘An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease.’ The primary aim is to assess the long-term safety of inclacumab in individuals with sickle cell disease (SCD) who have previously participated in an inclacumab clinical trial. This study is significant as it could provide insights into the prolonged use of inclacumab, potentially improving the management of SCD.

The intervention being tested is inclacumab, a drug administered intravenously at a dose of 30 mg/kg every 12 weeks. Inclacumab is intended to offer a therapeutic option for managing sickle cell disease by targeting specific pathways involved in the disease process.

The study follows an interventional design with a single-group assignment. There is no allocation or masking involved, as all participants receive the treatment. The primary purpose of the study is treatment, focusing on the safety profile of long-term inclacumab administration.

The study began on March 29, 2022, and the last update was submitted on July 8, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results that could impact clinical practices and market dynamics.

The ongoing study could influence Pfizer’s stock performance positively if the results demonstrate a favorable safety profile for inclacumab, enhancing investor confidence. In the competitive landscape of sickle cell disease treatments, successful outcomes could position Pfizer advantageously against other pharmaceutical companies.

The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.